Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity

被引：3
|
作者：
Karim, Lina Abdul [1 ]
Kallakury, Bhaskar V. S. [1 ]
Chahine, Joeffrey J. [1 ]
Sheehan, Christine E. [2 ]
Ross, Jeffrey S. [2 ,3 ]
机构：
[1] Medstar Georgetown Univ Hosp NW, Dept Pathol & Lab Med, Washington, DC 20057 USA
[2] Albany Med Coll, Dept Pathol, Albany, NY 12208 USA
[3] Fdn Med Inc, Cambridge, MA USA
来源：
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2018年 / 26卷 / 02期
关键词：
D O I：
10.1097/PAI.0000000000000609
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
引用
收藏
页码：E22 / E22
页数：1
相关论文
共 50 条
  • [31] Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
    Sughayer, Maher A.
    Alnaimy, Farah
    Alsughayer, Anas M.
    Qamhia, Naim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 663 - 666
  • [32] Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types
    Nakasaki, Manando
    Fadare, Oluwole
    Patel, Sandip
    Hansel, Donna
    LABORATORY INVESTIGATION, 2017, 97 : 532A - 532A
  • [33] PD-L1 (SP142) Immunohistochemistry in Clinical Metastatic Breast Carcinomas and its Association with Survival
    Shafi, Saba
    Challa, Bindu
    Parwani, Anil
    Li, Zaibo
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 192 - 194
  • [34] Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples.
    Scott, Marietta
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Barker, Craig
    Scorer, Paul
    Rebelatto, Marlon
    Al-Masri, Hytham
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [35] PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
    Yoon Jin Cha
    Dooreh Kim
    Soong June Bae
    Sung Gwe Ahn
    Joon Jeong
    Hye Sun Lee
    Soyoung Jeon
    Tae-Kyung Yoo
    Woo-Chan Park
    Chang Ik Yoon
    Scientific Reports, 11
  • [36] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
    Wilberger, Adam
    Aisner, Dara
    Merrick, Daniel T.
    MODERN PATHOLOGY, 2018, 31 : 756 - 757
  • [37] PD-L1 status by SP142 and sp263 immunohistochemistry in triple-negative breast cancer
    Cordoba, A.
    Mercado, M. D. R.
    Amat, I.
    Beloqui, R.
    Aguiar, B.
    Rodriguez, Y.
    Guerrero-Setas, D.
    VIRCHOWS ARCHIV, 2020, 477 : S44 - S44
  • [38] Comments on the Article by Miura et al.: "Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests"
    Yatabe, Yasushi
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (03):
  • [39] Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types
    Nakasaki, Manando
    Fadare, Oluwole
    Patel, Sandip
    Hansel, Donna
    MODERN PATHOLOGY, 2017, 30 : 532A - 532A
  • [40] Determination of inter-observer agreement in the immunohistochemical interpretation of PD-L1 clones 22C3 and SP142 in triple-negative breast cancer (TNBC)
    Abreu, R.
    Peixoto, R.
    Corassa, M.
    Nunes, W.
    Neotti, T.
    Rodrigues, T.
    Toledo, C.
    Domingos, T.
    Carraro, D.
    Gobbi, H.
    de Brot, M.
    de Paula, R.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S68 - S69
12345